Physician profile
Peter Jaber
NPI 1225001324
$4,184.34
in general payments reported to CMS, 2019-2025
24 companies · $923 in 2025
The $923 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $246 · 2021: $385 · 2022: $187 · 2023: $829 · 2024: $979 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,479.18 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,293.45 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $672.04 | 2019-2025 | |
| Amgen INC. | $287.59 | 2019-2025 | Otezla |
| Janssen Biotech, INC. | $237.06 | 2019-2025 | Tremfya, Simponi, Remicade |
| Genzyme Corporation | $236.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.31 | 2019-2025 | Dupixent |
| Ucb, INC. | $172.71 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $166.26 | 2019-2025 | |
| Pfizer INC. | $108.25 | 2020-2023 | |
| Lilly USA, LLC | $106.35 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $100.87 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $87.02 | 2023-2024 | Vtama |
| Leo Pharma INC. | $83.18 | 2022-2025 | Adbry, Anzupgo |
| Genentech USA, INC. | $81.55 | 2019 | |
| Celgene Corporation | $76.32 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $52.68 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $46.14 | 2024-2025 | Nemluvio |
| Dermira, INC. | $44.73 | 2019 | |
| Dusa Pharmaceuticals, INC. | $41.08 | 2019 | |
| Biofrontera INC. | $24.91 | 2019 | |
| Botanix Sb INC | $22.75 | 2025 | Sofdra |
| Organon LLC | $21.61 | 2025 | Hadlima |
| Helsinn Therapeutics (U.S.), INC. | $14.67 | 2021 | |
| Kyowa Kirin, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Jaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.